ABVC BIOPHARMA INC (ABVC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.00+1.51%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ABVC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 36.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
ABVC — private placement
Dated 2026-11-02
Entry into a Material Definitive Agreement Private Placement of Senior Convertible Promissory Notes On October 30, 2026 (the “ Closing Date ”), ABVC BioPharma, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ SPA ”) with certain accredited investors (the “ Purchasers ”) for the sale of original issue discount senior convertible promissory notes in an aggregate principal amount of $4,106,060 (the “ Notes ”) for an aggregate purchase price of $3,387,500 (the “ Private…
Why it matters: Licensing revenue can help fund the business. The last stated figure was about $1.28 million in Q3 2025.
Supportive ifQuarterly licensing revenue tops $1.28 million. The company reports partner payments or revenue from new deals.
Worry ifQuarterly licensing revenue falls below $1.28 million. No new partner payments are reported.
Why it matters: Losses narrowed in Q2 2026 but remained significant. A wider loss would reverse that progress.
Worry ifQuarterly operating loss exceeds $1.57 million, the Q1 2026 loss.
Less concerning ifQuarterly operating loss stays below $779,526, the Q2 2026 loss.
Why it matters: Cash from operations improved in Q2 2026 but remained negative. Further gains would show less cash use.
Supportive ifQuarterly cash from operations reaches zero or turns positive. It was negative $244,413 in Q2 2026.
Worry ifQuarterly cash from operations falls below negative $894,243. That was the Q1 2026 level.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$374 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $819 loss on $10,000 · 8.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,622 loss on $10,000 · 76.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.